Doctors’ professional associations in Canada are warning members about potential conflicts of interest stemming from financial ties to pharmaceutical manufacturers, as no public accountability system exists for these relationships. While other countries require disclosure of monetary transactions between doctors and drug companies, Canada lacks similar oversight, raising concerns about the influence on patient care. Studies indicate that such financial connections can lead to over-prescribing and compromised treatment quality. Experts stress the need for transparency in the healthcare system to ensure patients can make informed decisions.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
